ADVERTISEMENT
Search

Posted: Jan 18, 2022

FDA warns of dental problems associated with certain buprenorphine medications

FDA is drawing attention to dental problems linked to buprenorphine-containing medications that are dissolved under the tongue or placed against the inside of the cheek to treat opioid use disorder and pain.

Read more
Posted: Jan 10, 2022

New HIV PrEP guidelines call for clinicians to talk with patients about prevention meds

CDC now advises all clinicians to talk to their patients who are sexually active, including adolescents, about HIV preexposure prophylaxis (PrEP) at least once and to prescribe the prevention medication to anyone who requests them.

Read more
Posted: Dec 17, 2021

Study links statins with more aggressive diabetes progression

Patients with diabetes who used statins experienced less control of their diabetes than patients who did not take statins, suggests a new retrospective study published in JAMA Internal Medicine.

Read more
Posted: Dec 13, 2021

FDA puts clozapine REMS requirements on temporary hold

FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.

Read more
Posted: Nov 29, 2021

ISMP warns about confusion with co-packaging, labeling on monoclonal antibody products

The Institute for Safe Medication Practices (ISMP) is alerting health care providers about potential confusion over new alternative packaging for casirivimab and imdevimab. These monoclonal antibodies, administered together as REGEN-COV, are used for treating COVID-19. ISMP recently received multiple reports about these types of errors.

Read more
12

Related Articles

Advertisement
Advertisement
Advertisement
Advertisement
ADVERTISEMENT